$2.55
0.02[0.79%]
At close: Apr 25
$2.55
0[0.00%]
After Hours: 6:38PM EDT
DiaMedica Therapeutics
(NASDAQ:DMAC)DiaMedica Therapeutics Stock (NASDAQ:DMAC), Analyst Ratings, Price Targets, Predictions
DiaMedica Therapeutics Inc has a consensus price target of $13.5, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from Craig-Hallum, Craig-Hallum, and Oppenheimer on April 24, 2024, March 21, 2024, and March 21, 2024. With an average price target of $7.33 between Craig-Hallum, Craig-Hallum, and Oppenheimer, there's an implied 187.58% upside for DiaMedica Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Craig-Hallum
Oppenheimer
Lake Street
Roth Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for DiaMedica Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/24/2024 | DMAC | Buy Now | DiaMedica Therapeutics | $2.55 | 213.73% | Craig-Hallum | Alexander Nowak | → $8 | Assumes | → Buy | Get Alert |
| 03/21/2024 | DMAC | Buy Now | DiaMedica Therapeutics | $2.55 | 213.73% | Craig-Hallum | Alexander Nowak | $11 → $8 | Maintains | Buy | Get Alert |
| 03/21/2024 | DMAC | Buy Now | DiaMedica Therapeutics | $2.55 | 135.29% | Oppenheimer | Francois Brisebois | $7 → $6 | Reiterates | Outperform → Outperform | Get Alert |
| 06/22/2023 | DMAC | Buy Now | DiaMedica Therapeutics | $2.55 | 174.51% | Oppenheimer | Francois Brisebois | → $7 | Upgrade | Perform → Outperform | Get Alert |
| 07/07/2022 | DMAC | Buy Now | DiaMedica Therapeutics | $2.55 | 213.73% | Lake Street | Thomas Flaten | $14 → $8 | Maintains | Buy | Get Alert |
| 07/07/2022 | DMAC | Buy Now | DiaMedica Therapeutics | $2.55 | 370.59% | Craig-Hallum | Alexander Nowak | $18 → $12 | Maintains | Buy | Get Alert |
| 07/07/2022 | DMAC | Buy Now | DiaMedica Therapeutics | $2.55 | — | Oppenheimer | Francois Brisebois | — | Downgrade | Outperform → Perform | Get Alert |
| 06/30/2021 | DMAC | Buy Now | DiaMedica Therapeutics | $2.55 | 1154.9% | Roth Capital | Elemer Piros | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for DiaMedica Therapeutics (DMAC)?
The latest price target for DiaMedica Therapeutics (NASDAQ: DMAC) was reported by Craig-Hallum on April 24, 2024. The analyst firm set a price target for $8.00 expecting DMAC to rise to within 12 months (a possible 213.73% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for DiaMedica Therapeutics (DMAC)?
The latest analyst rating for DiaMedica Therapeutics (NASDAQ: DMAC) was provided by Craig-Hallum, and DiaMedica Therapeutics their buy rating.
When was the last upgrade for DiaMedica Therapeutics (DMAC)?
The last upgrade for DiaMedica Therapeutics Inc happened on June 22, 2023 when Oppenheimer raised their price target to $7. Oppenheimer previously had a perform for DiaMedica Therapeutics Inc.
When was the last downgrade for DiaMedica Therapeutics (DMAC)?
The last downgrade for DiaMedica Therapeutics Inc happened on July 7, 2022 when Oppenheimer changed their price target from N/A to N/A for DiaMedica Therapeutics Inc.
When is the next analyst rating going to be posted or updated for DiaMedica Therapeutics (DMAC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of DiaMedica Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for DiaMedica Therapeutics was filed on April 24, 2024 so you should expect the next rating to be made available sometime around April 24, 2025.
Is the Analyst Rating DiaMedica Therapeutics (DMAC) correct?
While ratings are subjective and will change, the latest DiaMedica Therapeutics (DMAC) rating was a with a price target of $0.00 to $8.00. The current price DiaMedica Therapeutics (DMAC) is trading at is $2.55, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.